A new class of drug called siRNA, a cousin of mRNA, can enter cells and stop a specific gene from producing a harmful protein. This enables highly targeted treatments, such as new drugs that reduce a type of cholesterol by over 95% with a single, long-lasting injection.

After decades of work, small interfering RNA (siRNA) has overcome delivery challenges to become a mature, "de-risked" platform, primarily for liver-directed targets. This now enables powerful medicines like a once-yearly injection for high cholesterol, representing a major public health breakthrough.

Stoke's therapy for Dravet syndrome employs a unique "upregulation" mechanism. Instead of knocking out a faulty gene or delivering a new one, its ASO targets the existing healthy gene to produce more of the needed NAV1.1 protein. This approach is specifically designed for haploinsufficient diseases where one gene copy is functional but insufficient.

The approvals of two different oligonucleotide constructs for the same indication (Arrowhead's siRNA vs. IONIS's ASO) mark a significant milestone. This direct competition between RNA modalities signifies a maturing market where companies now focus on determining which molecule is superior for specific targets.

While pioneering antisense oligonucleotide (ASO) therapies, Ionis faced immense scientific and financial hurdles with no guarantee of success. Competitors like Gilead abandoned the field, but Ionis persevered through decades of uncertainty, ultimately proving the viability of the new drug modality.

Instead of remaining a pure-play antisense oligonucleotide (ASO) company, Ionis's CEO diversified into siRNA and gene editing. He recognized that the company's core expertise in oligonucleotide therapeutics was broadly applicable, a move that energized the research organization.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

Instead of targeting the DMPK gene like competitors, Arthex's ATXO1 targets miR23B. This indirectly increases MBNL protein levels to compensate for sequestration while also destabilizing the toxic DMPK foci. This dual mechanism addresses both the downstream protein deficiency and the upstream genetic cause of the disease.

The commercial advantage of one-time CRISPR/Cas9 therapies is shrinking. Advancements in RNA modalities like siRNA now offer durable, long-lasting effects with a potentially safer profile. This creates a challenging risk-reward calculation for permanent gene edits in diseases where both technologies are applicable, especially as investor sentiment sours on CRISPR's long-term safety.